[Levofloxacin in children].
Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults. Its pharmacokinetic properties and microbiological spectrum, including penicillin non-susceptible Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Mycoplasma pneumoniae, suggest a potential interest in drug-resistant acute otitis media and community-acquired pneumonia. Only few studies have been performed in the paediatric population but they provided encouraging efficacy and safety data. Complementary data are needed before considering its use in Europe in the setting of a paediatric investigation plan.
Grimprel
E
E
Comité de Lutte contre les Infections Nosocomiales, Centre Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil. emmanuel.grimprel@trs.aphp.fr
Cohen
R
R
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D002648:Child; D017714:Community-Acquired Infections / Q000188:drug therapy; D006801:Humans; D064704:Levofloxacin; D009177:Mycoplasma pneumoniae / Q000187:drug effects; D015242:Ofloxacin / Q000627:therapeutic use*; D010033:Otitis Media / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin